PE20130690A1 - Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato - Google Patents

Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato

Info

Publication number
PE20130690A1
PE20130690A1 PE2012001383A PE2012001383A PE20130690A1 PE 20130690 A1 PE20130690 A1 PE 20130690A1 PE 2012001383 A PE2012001383 A PE 2012001383A PE 2012001383 A PE2012001383 A PE 2012001383A PE 20130690 A1 PE20130690 A1 PE 20130690A1
Authority
PE
Peru
Prior art keywords
metotrexate
rheumatoid arthritis
treatment
laquinimod
combination
Prior art date
Application number
PE2012001383A
Other languages
English (en)
Spanish (es)
Inventor
Eran Tarcic
Nora Tarcic
Joel Kaye
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130690(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20130690A1 publication Critical patent/PE20130690A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2012001383A 2010-03-03 2011-03-02 Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato PE20130690A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33937510P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
PE20130690A1 true PE20130690A1 (es) 2013-07-07

Family

ID=44531858

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001383A PE20130690A1 (es) 2010-03-03 2011-03-02 Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato

Country Status (22)

Country Link
US (1) US8501766B2 (cg-RX-API-DMAC7.html)
EP (1) EP2542079B1 (cg-RX-API-DMAC7.html)
JP (1) JP5819328B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130014523A (cg-RX-API-DMAC7.html)
CN (2) CN102781240A (cg-RX-API-DMAC7.html)
AU (1) AU2011223697B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012022187A2 (cg-RX-API-DMAC7.html)
CA (1) CA2791709A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012002424A1 (cg-RX-API-DMAC7.html)
CO (1) CO6630085A2 (cg-RX-API-DMAC7.html)
DK (1) DK2542079T3 (cg-RX-API-DMAC7.html)
EA (1) EA201290860A1 (cg-RX-API-DMAC7.html)
ES (1) ES2476368T3 (cg-RX-API-DMAC7.html)
MX (1) MX2012010066A (cg-RX-API-DMAC7.html)
NZ (1) NZ602478A (cg-RX-API-DMAC7.html)
PE (1) PE20130690A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501740A1 (cg-RX-API-DMAC7.html)
PT (1) PT2542079E (cg-RX-API-DMAC7.html)
SG (1) SG183513A1 (cg-RX-API-DMAC7.html)
SI (1) SI2542079T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011109531A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201207128B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101440982B1 (ko) * 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
ATE532515T1 (de) 2006-06-12 2011-11-15 Teva Pharma Stabile laquinimod-zubereitungen
RS53199B (sr) 2007-12-20 2014-06-30 Teva Pharmaceutical Industries Ltd. Stabilni preparati lakvinimoda
EP2337779B1 (en) * 2008-09-03 2017-04-19 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
AU2010260455A1 (en) * 2009-06-19 2012-02-02 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
JP5882208B2 (ja) * 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
RS55071B1 (sr) 2009-08-10 2016-12-30 Teva Pharma Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
BR112012021905A2 (pt) * 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
MX2014009373A (es) 2012-02-03 2014-08-27 Teva Pharma Uso de laquinimod para tratar pacientes con enfermedad de crohn que fallaron en la terapia de anti-tnfa de primera linea.
CN104114172A (zh) 2012-02-16 2014-10-22 泰华制药工业有限公司 N-乙基-n-苯基-1,2-二氢-4,5-二-羟基-1-甲基-2-氧代-3-喹啉甲酰胺、其制备和用途
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
EP2970129A2 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US20160038435A1 (en) 2013-03-14 2016-02-11 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
RS51019B (sr) 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
EP1365794A2 (en) 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
CA2528723A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US20060004019A1 (en) 2004-04-01 2006-01-05 Ivan Lieberburg Steroid sparing agents and methods of using same
EP1796710A4 (en) 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
US7560100B2 (en) 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR101440982B1 (ko) 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
RS52229B (sr) * 2005-10-26 2012-10-31 Merck Serono Sa. Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
WO2007100763A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
CA2644110A1 (en) 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2007139887A2 (en) 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
WO2007146331A1 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
ATE532515T1 (de) 2006-06-12 2011-11-15 Teva Pharma Stabile laquinimod-zubereitungen
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
JP2010513518A (ja) 2006-12-19 2010-04-30 メリマック ファーマシューティカルズ インコーポレーティッド 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
PL2187882T3 (pl) 2007-07-11 2013-05-31 Medicinova Inc Leczenie postępującej choroby neurodegeneracyjnej ibudilastem
RS53199B (sr) 2007-12-20 2014-06-30 Teva Pharmaceutical Industries Ltd. Stabilni preparati lakvinimoda
EP2337779B1 (en) 2008-09-03 2017-04-19 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
AU2010260455A1 (en) 2009-06-19 2012-02-02 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
JP5882208B2 (ja) 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
RS55071B1 (sr) 2009-08-10 2016-12-30 Teva Pharma Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
MX342001B (es) 2010-03-03 2016-09-09 Teva Pharmaceutical Ind Ltd * Tratamiento de artritis por lupus usando laquinimod.
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
CN102985090B (zh) 2010-07-09 2014-11-26 泰华制药工业有限公司 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途
SG10201509831XA (en) 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
EP2736336A4 (en) 2011-07-28 2015-03-04 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND INTERFERON-BETA
KR20140054166A (ko) 2011-07-28 2014-05-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 글라티라머 아세테이트의 병용에 의한 다발성 경화증의 치료

Also Published As

Publication number Publication date
CA2791709A1 (en) 2011-09-09
CN102781240A (zh) 2012-11-14
DK2542079T3 (da) 2014-08-25
NZ602478A (en) 2014-09-26
EP2542079A4 (en) 2013-07-24
AU2011223697A1 (en) 2012-10-11
CL2012002424A1 (es) 2012-12-21
AU2011223697B2 (en) 2016-07-14
EA201290860A1 (ru) 2013-04-30
CO6630085A2 (es) 2013-03-01
ZA201207128B (en) 2014-04-30
WO2011109531A1 (en) 2011-09-09
KR20130014523A (ko) 2013-02-07
US8501766B2 (en) 2013-08-06
MX2012010066A (es) 2012-10-03
BR112012022187A2 (pt) 2015-09-22
ES2476368T3 (es) 2014-07-14
SG183513A1 (en) 2012-09-27
CN105796556A (zh) 2016-07-27
EP2542079B1 (en) 2014-05-21
EP2542079A1 (en) 2013-01-09
PH12012501740A1 (en) 2012-11-12
US20110218203A1 (en) 2011-09-08
JP5819328B2 (ja) 2015-11-24
PT2542079E (pt) 2014-07-18
SI2542079T1 (sl) 2014-08-29
JP2013521304A (ja) 2013-06-10

Similar Documents

Publication Publication Date Title
PE20130690A1 (es) Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato
PE20130496A1 (es) Tratamiento de artritis por lupus usando laquinimod
PE20121136A1 (es) Composiciones de pelicula sublinguales y bucales
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
NZ599847A (en) Pharmaceutical composition comprising a glp-1 agonist and methionine
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
MY158504A (en) Fatty acid niacin conjugates and their uses
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
ECSP109905A (es) Moduladores de receptor 7 tipo toll
MX2010007083A (es) Combinacion anti-retroviral.
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MA31706B1 (fr) Formulations galéniques de composés organiques
WO2008094910A3 (en) Hyaluronate compositions
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
CL2011002213A1 (es) Sal de adicion cristalina de (i) trometamina con (ii) un derivado de acido azabifenilaminobenzoico; composicion farmaceutica que comprende a la sal y otros agentes terapeuticos; combinacion farmaceutica; y su uso para el tratamiento de artritis reumatoide, artritis psoriasica, espondilitis anquilosante, esclerosis multiple, entre otras
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
ECSP067074A (es) Derivados de 4-fenil-pirimidina-2-carbonitrilo
PE20120515A1 (es) Formulaciones de deferiprona
CO6331430A2 (es) Composicion farmaceutica que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia
CL2008003584A1 (es) Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva.

Legal Events

Date Code Title Description
FC Refusal